Unicycive Therapeutics: A Catalyst Play With Real Fundamental Upside

Unicycive Therapeutics is valued at $8/share, with $2/share in cash and the pipeline—primarily OLC—valued at $6/share. OLC targets hyperphosphatemia by reducing pill burden, aiming for improved patient adherence, with a PDUFA date set for June 29, 2026. Key risks include payer acceptance of premium pricing, patent term uncertainty, and lack of outcomes data supporting improved adherence.